CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Vorinostat, Lenalinomide and Dexamethasonedrug
Likely dose
Vorinostat, Lenalinomide and Dexamethasone 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01502085
NCT01502085Phase 2Completed
CompareCT.gov

A Phase IIb Trial of Vorinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma Patients Refractory to Previous Lenalidomide Containing Regimens

Hackensack Meridian Health·interventional·Posted Dec 30, 2011·Updated Apr 3, 2026

In Brief

A Phase 2 clinical trial evaluating Vorinostat, Lenalinomide and Dexamethasone for Multiple Myeloma. Completed, enrolled 25 participants across 1 site.

Detailed Summary

Phase IIb clinical trial to determine if resistance to a lenalidomide containing regimen can be overcome by the addition of vorinostat, in patients with relapsed and refractory multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 30, 2011
Enrollment StartDec 1, 2011
Primary CompletionDec 1, 2015
Study CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 14.5 years ago

Interventions

Vorinostat, Lenalinomide and Dexamethasonedrug

Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21 \* Lenalidomide dose for patients with renal impairment (CrCL\<50ml/min) has be dose adjusted according to package insert Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above